Recombinant Protein Production News and Research

RSS
Scil Technology receives public research grant for novel rheumatoid arthritis treatments

Scil Technology receives public research grant for novel rheumatoid arthritis treatments

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Study shows immune therapy can prevent pregnancy in mammals including humans

Study shows immune therapy can prevent pregnancy in mammals including humans

Immune therapy can control fertility in mammals

Immune therapy can control fertility in mammals

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

Baxter fourth quarter net income declines 26% to $423 million

Baxter fourth quarter net income declines 26% to $423 million

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences and BGI complete CHO-K1 genome sequencing

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine

Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine

Science and precedent do not support biosimilar approach for plasma protein therapies

Science and precedent do not support biosimilar approach for plasma protein therapies

FDA accepts IND application for vaccine candidate based on iBioLaunch technology platform

FDA accepts IND application for vaccine candidate based on iBioLaunch technology platform

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

Life Technologies finalizes cell line license agreement for recombinant protein production

Life Technologies finalizes cell line license agreement for recombinant protein production

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

BioMimetic completes 100 day PMA meeting with FDA for Augment Bone Graft

BioMimetic completes 100 day PMA meeting with FDA for Augment Bone Graft